Collplant Biotechnologies vs Korsana Biosciences
Collplant Biotechnologies and Korsana Biosciences are similar in size: $2.4m and $2.1m of revenue in their latest fiscal years. Collplant Biotechnologies grew faster (360.4% against 3.7%). Korsana Biosciences kept more of each dollar of sales as profit: a net margin of -170.1% against -484.6%. Collplant Biotechnologies carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | Korsana BiosciencesKRSA, 2025 |
|---|---|---|
| Revenue | $2.4m | $2.1m |
| Revenue growth | 360.4% | 3.7% |
| Net income | −$11.5m | −$3.5m |
| Operating margin | -484.3% | -239.8% |
| Net margin | -484.6% | -170.1% |
| Return on equity | -117.6% | -39.3% |
| Free cash flow | −$9.4m | −$3.3m |
| Cash | $5.6m | $3.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $54.5m | $138m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |